Company / Capital Expenditures
Vir Biotechnology, Inc. Capital Expenditures History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$4.8M
FY2025
5-year range
$4.8M / $21.6M
FY2021-FY2025
Trend
-33.8%
vs FY2024
Sector context
#73 of 194
Health Care
What the data says
At $5M, Vir Biotechnology, Inc.'s capital expenditures ranks #73 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 9 years, ranging from $3M in FY2017 to $22M in FY2023.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of -5.9%.
Declined from $22M to $5M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -9.6%
- 5-Year CAGR
- -5.9%
- 10-Year CAGR
- -
Sector benchmark
#73 of 194 in Health CareTop 38% of 194This company $4.8M Sector average $117.5M
▼
-95.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -5.9%, indicating a declining trend.
- In FY2025, capital expenditures decreased 33.8% year-over-year.
- Ranks #73 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.8M | -33.8% |
| FY2024 | $7.3M | -66.2% |
| FY2023 | $21.6M | +229.4% |
| FY2022 | $6.5M | -26.7% |
| FY2021 | $8.9M | +36.5% |
| FY2020 | $6.5M | -26.7% |
| FY2019 | $8.9M | +9.1% |
| FY2018 | $8.2M | +198.8% |
| FY2017 | $2.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026